Quantcast

Latest Boehringer Ingelheim Corporation Stories

2014-05-14 20:23:28

-- Results from two Phase III studies (LUX-Lung 3 and LUX-Lung 6) add to the body of evidence supporting the importance of first-line treatment with afatinib in patients whose tumors express the EGFR

2014-04-30 12:30:17

- First results of the pivotal Phase 3 INPULSIS(TM) trials investigating the efficacy and safety of nintedanib, an investigational compound, in the treatment of idiopathic pulmonary fibrosis (IPF)

2014-04-17 08:28:00

RIDGEFIELD, Conn., April 17, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S.

2014-04-14 12:34:34

RIDGEFIELD, Conn. and INDIANAPOLIS, April 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Lilly; NYSE: LLY) today announced the U.S.

2014-04-08 12:31:49

Three pivotal trials showed PRADAXA as non-inferior to warfarin in reduction of DVT and PE recurrence; fourth pivotal trial showed PRADAXA reduced risk of recurrence by 92 percent compared to placebo RIDGEFIELD,

2014-04-07 08:31:34

Three pivotal trials showed PRADAXA as non-inferior to warfarin in reduction of DVT and PE recurrence; fourth pivotal trial showed PRADAXA reduced risk of recurrence by 92 percent compared to placebo RIDGEFIELD,

2014-03-28 08:27:23

Cardiologists also believe their patients' top concern is the fear of experiencing a clot that leads to a stroke; real-world challenges may influence treatment decisions RIDGEFIELD, Conn.,

2014-03-24 08:28:21

Presentations to include research around antidote for dabigatran, a post-hoc analysis of data from the RE-LY® trial and data from the GLORIA(TM)-AF registry RIDGEFIELD, Conn., March 24, 2014

2014-03-21 08:24:55

Positive opinion is based on data from one of the largest clinical registration programs in its class, involving more than 13,000 adults with type 2 diabetes RIDGEFIELD, Conn.


Word of the Day
logocentrism
  • The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.
The word 'logocentrism' is a blend of logo- +‎ centrism.
Related